Metaxalone-d6

• Description:

  Metaxalone-d6 is deuterium labeled Metaxalone. Metaxalone (AHR438; NSC170959) is an FDA-approved muscle relaxant. Metaxalone acts mainly on the central nervous system and achieves muscle relaxation by inhibiting polysynaptic reflex arcs. In addition, Metaxalone is an inhibitor of MAO-A, which has anti-inflammatory and antioxidant effects. Metaxalone inhibits IL-1β-induced inflammatory phenotype, modulates NF-κB and other related signaling pathways, and decreases MAO-A expression and activity in IL-1β-treated microglia[1][2][3].

• Product Name Alternative:

  AHR438-d6; NSC170959-d6

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  Isotope-Labeled Compounds; NF-κB; PGC-1α

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Metabolic Enzyme/Protease; NF-κB; Others

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  [2H]C ([2H]) ([2H]) C1=CC (C ([2H]) ([2H]) [2H]) =CC (OCC2OC (NC2) =O) =C1

• Molecular Formula:

  C12H9D6NO3

• Molecular Weight:

  227.29

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Pallio G, et al. MAO-A Inhibition by Metaxalone Reverts IL-1β-Induced Inflammatory Phenotype in Microglial Cells. Int J Mol Sci. 2021;22 (16) :8425. |[3]Stanko JR. Review of oral skeletal muscle relaxants for the craniomandibular disorder (CMD) practitioner. Cranio. 1990 Jul;8 (3) :234-43.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  1189944-95-3